P3 Health Partners Inc

P3 Health Partners, Inc. is a population health care management company, which engages in the provision of professional support services to doctors and clinicians. The firm offers capital efficient care model, data and technology, physician leadership and community outreach tools to create enhanced patient outcomes and experiences. The company was founded by Sherif Abdou and Amir Bacchus on August 20, 2020 and is headquartered in Henderson, NV.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

P3 Health Partners Inc reports robust Q4 performance and eyes profitability in 2024

P3 Health Partners Inc demonstrated strong financial performance and strategic initiatives during the Q4 2022 earnings call, positioning the company for future growth and profitability. While facing challenges in managing costs and optimizing margins, the company remains optimistic about its financial outlook and growth prospects. By leveraging opportunities in market expansion and operational enhancements, P3 Health Partners Inc aims to achieve positive cash flow in 2024.

P3 Health Partners Inc reports improved Q1 performance and growth outlook

P3 Health Partners Inc showed improved financial performance and operational metrics in Q1.
The company is on track towards profitability, with a focus on growth and healthcare transformation.
Challenges include managing EBITDA losses, COVID impact, and provider relationships.
Opportunities lie in further improving metrics, expanding in newer markets, and enhancing care management.

P3 Health Partners Inc reports strong Q2 earnings and growth opportunities

P3 Health Partners Inc (PIII) demonstrated positive financial performance in Q2 2023, with strong revenue growth and improved margins.
The company's focus on operational efficiency, quality improvements, and growth objectives positions it well for future success.
While facing challenges in managing expenses and achieving profitability, P3 Health Partners Inc (PIII) has opportunities for growth and market expansion.
Overall, the company's sustained demand, efficient operations, and progress towards profitability indicate a promising outlook for stakeholders.

P3 Health Partners Inc reports solid Q3 results, eyes growth

P3 Health Partners Inc delivered a strong performance in Q3, focusing on revenue growth, cost management, and profitability.
While facing challenges such as timing issues and payer negotiations, the company remains optimistic about its future prospects.
Opportunities for growth include expanding partnerships, optimizing operational efficiency, and providing clearer financial guidance to stakeholders.
Overall, PIII's strategic initiatives position it well for continued success, with a positive outlook for 2024 and beyond.

P3 Health Partners reports strong 2023 growth and positive 2024 outlook

P3 Health Partners Inc delivered robust financial performance in 2023.
Strategic initiatives led to improved margins and revenue growth.
Challenges include managing expenses and potential regulatory changes.
Opportunities lie in partnerships, persistency rates, and revenue expansion.

P3 Health Partners reports strong Q1 earnings, eyes AI growth

P3 Health Partners Inc's Q1 2024 showed strong revenue growth and operational efficiencies.
The company is confident in achieving its EBITDA guidance through strategic partnerships and focus on high-risk populations.
Challenges include managing cash flow, capital requirements for growth, and effective high-risk population management.
Opportunities lie in AI partnerships, data analytics tools, and deeper provider engagement for better care outcomes.

P3 Health Partners reports robust Q2 results and eyes growth

P3 Health Partners showed strong performance in Q2 with revenue growth, cost reduction, and improved EBITDA loss. The company's focus on expense management and balance sheet strength position it well for future growth. Challenges remain in managing medical costs and achieving profitability, but opportunities for expansion and improved financial performance are evident.

P3 Health Partners reports Q3 loss, plans improvements for 2025

P3 Health Partners Inc faced challenges in Q3 2024 with a $71 million adjusted EBITDA loss, driven by retroactive adjustments and high medical utilization. Despite this, the company plans significant improvements in contracts, efficiency, and data analytics for 2025. Opportunities exist in optimizing working capital, strategic financing, and focusing on high-performance markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of P3 Health Partners Inc. (NASDAQ: PIII) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of P3 Health Partners Inc. to Contact Law Firm

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference, on Tuesday, December 3, 2024, in Boca Raton, FL, at 3:30 pm Eastern Time. A live webcast of the presentation will be available the following day on P3's Investor Relations Website: https://ir.p3.

P3 Health Partners to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced the Company will participate in the following upcoming investor conferences: - The 3rd Annual Needham Virtual Healthcare IT 1x1 Conference on Wednesday, November 20, 2024 - The BTIG Digital Health Forum on Monday, November 25, 2024 About P3 Health Partners (NASDAQ: PIII) P3 Health Partners Inc. is a leading p.

P3 Health Partners to Participate in Upcoming Investor Conferences

P3 Health Partners Inc. (NASDAQ:PIII ) Q3 2024 Results Conference Call November 12, 2024 4:30 PM ET Company Participants Ryan Halsted - Investor Relations Aric Coffman - Chief Executive Officer Leif Pedersen - Chief Financial Officer Amir Bacchus - Chief Medical Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Josh Raskin - Nephron Research Jenny Shen - BTIG Jack Senft - William Blair Operator Good day, and welcome to P3 Health Partners Third Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

P3 Health Partners Inc. (PIII) Q3 2024 Earnings Call Transcript

P3 Health Partners Inc. (PIII) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.12 per share a year ago.

P3 Health Partners Inc. (PIII) Reports Q3 Loss, Misses Revenue Estimates

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2024. “As we execute on our strategic initiatives, we believe P3 will be well-positioned to unlock the value built within our platform and generate sustainable, profitable growth in the medium and long term,” said Aric Coffman, CEO of P3. “We hav.

P3 Health Partners Announces Third Quarter 2024 Results

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into P3 Health Partners, Inc.

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into P3 Health Partners

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for third quarter 2024 and file its Quarterly Report on Form 10-Q on Tuesday, November 12, 2024. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Th.

P3 Health Partners Schedules Third Quarter 2024 Earnings Release and Conference Call

/ ACCESSWIRE / October 23, 2024 / NEW YORK, NY / ACCESSWIRE / October 23, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into P3 Health Partners, Inc.

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that management is scheduled to present at the LD Micro Main Event XVII Conference on Wednesday, October 30, 2024, in Los Angeles, CA, at 2:30 pm Eastern Time. A live webcast of the presentation will be available on P3's Investor Relations Website: https://ir.p3hp.org/. About P3 Health Partners (NASDAQ: PIII).

P3 Health Partners to Present at the LD Micro Main Event XVII

NEW YORK, NY / ACCESSWIRE / October 16, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into P3 Health Par

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into P3 Health Partners, Inc.

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into P3 Health Partners, Inc

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into P3 Health Partners, Inc.

NEW YORK, NY / ACCESSWIRE / September 17, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into P3 Health Partn

thredUP

XWELL Inc

The Dow Jones index closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.

ThredUp And 2 Other Stocks Under $2 Executives Are Buying

P3 Health Partners (PIII) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

P3 Health Partners (PIII) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3") (NASDAQ: PIII), a patient-centered and physician-led population health management company, announced today that Leif Pedersen, an experienced finance, operational and value-based care executive, will join the company as chief financial officer (CFO) effective October 1, 2024. Pedersen succeeds Atul Kavthekar, who will continue as CFO until September 30, 2024, after which he will serve as a Strategic Advisor to the company. Pederse.

P3 Health Partners Names Leif Pedersen New Chief Financial Officer

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own P3 Health Partners, Inc. ("PII" or the "Company") (NASDAQ:PIII) stock purchased prior to December 1, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Foresight Acquisition Corp. (FORE)), and whether the Board of PII harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into P3 Health Pa

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company will participate at the following upcoming investor conferences: - The 2024 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 4, 2024 - The Lake Street Best Ideas Growth Conference in New York, NY on Thursday, September 12, 2024 About P3 Health Partners (NASDAQ: PIII): P3 Health Partners Inc. is a leading population heal.

P3 Health Partners to Present at Upcoming Investor Conferences

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, P3 Health Partners (PIII) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

P3 Health Partners (PIII) Shows Fast-paced Momentum But Is Still a Bargain Stock

P3 Health Partners Inc. (NASDAQ:PIII ) Q2 2024 Earnings Call August 7, 2024 4:30 PM ET Company Participants Ryan Halsted - Investor Relations Aric Coffman - Chief Executive Officer Atul Kavthekar - Chief Financial Officer Amir Bacchus - Chief Medical Officer Bill Bettermann - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Josh Raskin - Nephron Research Jenny Shen - BTIG Ryan Langston - TD Cowen Jack Senft - William Blair Operator Good day, and welcome to the P3 Health Partners Second Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

P3 Health Partners Inc. (PIII) Q2 2024 Earnings Call Transcript

P3 Health Partners Inc. (PIII) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago.

P3 Health Partners Inc. (PIII) Reports Q2 Loss, Tops Revenue Estimates

HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the second quarter ended June 30, 2024. “In the second quarter, we experienced continued growth in our top line while simultaneously enhancing our balance sheet through a successful capital raise,” said Aric Coffman, CEO of P3. “Building on P3's key strengths, I have identified sever.

News for P3 Health Partners Inc Stock (PIII)